Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Feb;79(3-4):515–519. doi: 10.1038/sj.bjc.6690080

Early death during chemotherapy in patients with small-cell lung cancer: derivation of a prognostic index for toxic death and progression

U N Lassen 1, K Østerlind 2, F R Hirsch 1, B Bergman 3, P Dombernowsky 4, H H Hansen 1
PMCID: PMC2362437  PMID: 10027322

Abstract

Based on an increased frequency of early death (death within the first treatment cycle) in our two latest randomized trials of combination chemotherapy in small-cell lung cancer (SCLC), we wanted to identify patients at risk of early non-toxic death (ENTD) and early toxic death (ETD). Data were stored in a database and logistic regression analyses were performed to identify predictive factors for early death. During the first cycle, 118 out of 937 patients (12.6%) died. In 38 patients (4%), the cause of death was sepsis. Significant risk factors were age, performance status (PS), lactate dehydrogenase (LDH) and treatment with epipodophyllotoxins and platinum in the first cycle (EP). Risk factors for ENTD were age, PS and LDH. Extensive stage had a hazard ratio of 1.9 (P = 0.07). Risk factors for ETD were EP, PS and LDH, whereas age and stage were not. For EP, the hazard ratio was as high as 6.7 (P = 0.0001). We introduced a simple prognostic algorithm including performance status, LDH and age. Using a prognostic algorithm to exclude poor-risk patients from trials, we could minimize early death, improve long-term survival and increase the survival differences between different regimens. We suggest that other groups evaluate our algorithm and exclude poor prognosis patients from trials of dose intensification. © 1999 Cancer Research Campaign

Keywords: small-cell lung cancer, chemotherapy, early death, prognostis factors, sepsis

Full Text

The Full Text of this article is available as a PDF (85.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bork E., Ersbøll J., Dombernowsky P., Bergman B., Hansen M., Hansen H. H. Teniposide and etoposide in previously untreated small-cell lung cancer: a randomized study. J Clin Oncol. 1991 Sep;9(9):1627–1631. doi: 10.1200/JCO.1991.9.9.1627. [DOI] [PubMed] [Google Scholar]
  2. Jackson D. V., Jr, Case L. D., Zekan P. J., Powell B. L., Caldwell R. D., Bearden J. D., Nelson E. C., Muss H. B., Cooper M. R., Richards F., 2nd Improvement of long-term survival in extensive small-cell lung cancer. J Clin Oncol. 1988 Jul;6(7):1161–1169. doi: 10.1200/JCO.1988.6.7.1161. [DOI] [PubMed] [Google Scholar]
  3. Johnson D. H., Einhorn L. H., Birch R., Vollmer R., Perez C., Krauss S., Omura G., Greco F. A. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol. 1987 Nov;5(11):1731–1738. doi: 10.1200/JCO.1987.5.11.1731. [DOI] [PubMed] [Google Scholar]
  4. Kalwinsky D. K., Look A. T., Ducore J., Fridland A. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemic lymphoblasts. Cancer Res. 1983 Apr;43(4):1592–1597. [PubMed] [Google Scholar]
  5. Klasa R. J., Murray N., Coldman A. J. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991 Mar;9(3):499–508. doi: 10.1200/JCO.1991.9.3.499. [DOI] [PubMed] [Google Scholar]
  6. Kristjansen P. E., Hansen H. H. Management of small cell lung cancer: a summary of the Third International Association for the Study of Lung Cancer Workshop on Small Cell Lung Cancer. J Natl Cancer Inst. 1990 Feb 21;82(4):263–266. doi: 10.1093/jnci/82.4.263. [DOI] [PubMed] [Google Scholar]
  7. Lassen U., Kristjansen P. E., Osterlind K., Bergman B., Sigsgaard T. C., Hirsch F. R., Hansen M., Dombernowsky P., Hansen H. H. Superiority of cisplatin or carboplatin in combination with teniposide and vincristine in the induction chemotherapy of small-cell lung cancer. A randomized trial with 5 years follow up. Ann Oncol. 1996 Apr;7(4):365–371. doi: 10.1093/oxfordjournals.annonc.a010603. [DOI] [PubMed] [Google Scholar]
  8. Morittu L., Earl H. M., Souhami R. L., Ash C. M., Tobias J. S., Geddes D. M., Harper P. G., Spiro S. G. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer. Br J Cancer. 1989 May;59(5):801–804. doi: 10.1038/bjc.1989.167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Osterlind K., Sörenson S., Hansen H. H., Dombernowsky P., Hirsch F. R., Hansen M., Rørth M. Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung. Cancer Res. 1983 Dec;43(12 Pt 1):6085–6089. [PubMed] [Google Scholar]
  10. Pflüger K. H., Schmidt L., Merkel M., Jungclas H., Havemann K. Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide. Cancer Chemother Pharmacol. 1987;20(1):59–66. doi: 10.1007/BF00252961. [DOI] [PubMed] [Google Scholar]
  11. Randomised trial of four-drug vs less intensive two-drug chemotherapy in the palliative treatment of patients with small-cell lung cancer (SCLC) and poor prognosis. Medical Research Council Lung Cancer Working Party. Br J Cancer. 1996 Feb;73(3):406–413. doi: 10.1038/bjc.1996.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Souhami R. L., Spiro S. G., Rudd R. M., Ruiz de Elvira M. C., James L. E., Gower N. H., Lamont A., Harper P. G. Five-day oral etoposide treatment for advanced small-cell lung cancer: randomized comparison with intravenous chemotherapy. J Natl Cancer Inst. 1997 Apr 16;89(8):577–580. doi: 10.1093/jnci/89.8.577. [DOI] [PubMed] [Google Scholar]
  13. Stahel R. A., Takvorian R. W., Skarin A. T., Canellos G. P. Autologous bone marrow transplantation following high-dose chemotherapy with cyclophosphamide, BCNU and VP-16 in small cell carcinoma of the lung and a review of current literature. Eur J Cancer Clin Oncol. 1984 Oct;20(10):1233–1238. doi: 10.1016/0277-5379(84)90252-9. [DOI] [PubMed] [Google Scholar]
  14. Stephens R. J., Girling D. J., Machin D. Treatment-related deaths in small cell lung cancer trials: can patients at risk be identified? Medical Research Council Lung Cancer Working Party. Lung Cancer. 1994 Sep;11(3-4):259–274. doi: 10.1016/0169-5002(94)90546-0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES